228 related articles for article (PubMed ID: 17721615)
1. Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats.
Wienen W; Stassen JM; Priepke H; Ries UJ; Hauel N
Thromb Haemost; 2007 Aug; 98(2):333-8. PubMed ID: 17721615
[TBL] [Abstract][Full Text] [Related]
2. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate.
Wienen W; Stassen JM; Priepke H; Ries UJ; Hauel N
Thromb Haemost; 2007 Jul; 98(1):155-62. PubMed ID: 17598008
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis.
Wienen W; Stassen JM; Priepke H; Ries UJ; Hauel N
J Thromb Haemost; 2007 Jun; 5(6):1237-42. PubMed ID: 17362226
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
Stangier J; Rathgen K; Stähle H; Gansser D; Roth W
Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
[TBL] [Abstract][Full Text] [Related]
5. Antithrombotic activity of HY023016, a novel Dabigatran prodrug evaluated in animal thrombosis models.
Li YZ; Gong GQ; Yang WH; Wang XH; Jiang ML; Zhou Y; Yang XZ; Xu YG; He GW
Thromb Res; 2013 May; 131(5):425-35. PubMed ID: 23535565
[TBL] [Abstract][Full Text] [Related]
6. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin.
Eisert WG; Hauel N; Stangier J; Wienen W; Clemens A; van Ryn J
Arterioscler Thromb Vasc Biol; 2010 Oct; 30(10):1885-9. PubMed ID: 20671233
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves.
McKellar SH; Abel S; Camp CL; Suri RM; Ereth MH; Schaff HV
J Thorac Cardiovasc Surg; 2011 Jun; 141(6):1410-6. PubMed ID: 21429525
[TBL] [Abstract][Full Text] [Related]
8. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
van Ryn J; Stangier J; Haertter S; Liesenfeld KH; Wienen W; Feuring M; Clemens A
Thromb Haemost; 2010 Jun; 103(6):1116-27. PubMed ID: 20352166
[TBL] [Abstract][Full Text] [Related]
9. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.
Baetz BE; Spinler SA
Pharmacotherapy; 2008 Nov; 28(11):1354-73. PubMed ID: 18956996
[TBL] [Abstract][Full Text] [Related]
10. In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves.
Maegdefessel L; Linde T; Krapiec F; Hamilton K; Steinseifer U; van Ryn J; Raaz U; Buerke M; Werdan K; Schlitt A
Thromb Res; 2010 Sep; 126(3):e196-200. PubMed ID: 20659761
[TBL] [Abstract][Full Text] [Related]
11. Dabigatran: new drug. Continue to use heparin, a better-known option.
Prescrire Int; 2009 Jun; 18(101):97-9. PubMed ID: 19637411
[TBL] [Abstract][Full Text] [Related]
12. The pharmacology and therapeutic use of dabigatran etexilate.
Sarah S
J Clin Pharmacol; 2013 Jan; 53(1):1-13. PubMed ID: 23400738
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery.
Trocóniz IF; Tillmann C; Liesenfeld KH; Schäfer HG; Stangier J
J Clin Pharmacol; 2007 Mar; 47(3):371-82. PubMed ID: 17322149
[TBL] [Abstract][Full Text] [Related]
14. S35972, a direct-acting thrombin inhibitor with high oral bioavailability and antithrombotic efficacy.
Rupin A; Marx I; Vallez MO; Mennecier P; Gloanec P; De Nanteuil G; Verbeuren TJ
J Thromb Haemost; 2011 Jul; 9(7):1375-82. PubMed ID: 21481181
[TBL] [Abstract][Full Text] [Related]
15. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.
Eriksson BI; Dahl OE; Ahnfelt L; Kälebo P; Stangier J; Nehmiz G; Hermansson K; Kohlbrenner V
J Thromb Haemost; 2004 Sep; 2(9):1573-80. PubMed ID: 15333033
[TBL] [Abstract][Full Text] [Related]
16. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.
Stangier J; Clemens A
Clin Appl Thromb Hemost; 2009; 15 Suppl 1():9S-16S. PubMed ID: 19696042
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment.
Stangier J; Stähle H; Rathgen K; Roth W; Shakeri-Nejad K
J Clin Pharmacol; 2008 Dec; 48(12):1411-9. PubMed ID: 18827075
[TBL] [Abstract][Full Text] [Related]
18. Dabigatran etexilate (Pradaxa)--a new oral anticoagulant.
Med Lett Drugs Ther; 2010 Nov; 52(1351):89-90. PubMed ID: 21068702
[TBL] [Abstract][Full Text] [Related]
19. Dabigatran etexilate for the prophylaxis of venous thromboembolism after hip or knee replacement rationale for dose regimen.
Dahl OE
Clin Appl Thromb Hemost; 2009; 15 Suppl 1():17S-24S. PubMed ID: 19696041
[TBL] [Abstract][Full Text] [Related]
20. Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug.
Park HD; Lee SH; Kim TH; Lee SH; Cho KH; Kim A
Bioorg Med Chem Lett; 2013 Sep; 23(17):4779-84. PubMed ID: 23899618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
